The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines
Date
2020-06-15Author
Kochhar, Sonali
Kim, Denny
Excler, ean-Louis
Condit, Richard C.
Robertson, James S.
Drew, Stephen
Whelan, Mike
Wood, David
Fast, Patricia E.
Gurwith, Marc
Klug, Bettina
Khuri-Bulos, Najwa
Smith, Emily R.
Chen, Robert T
For the Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)
Metadata
Show full item record
Documentos PDF
Summary in foreign language
Several protein vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of protein vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of such a vaccine platform. The structured and standardized assessment provided by the template would also help contribute to improved public acceptance and communication of licensed protein vaccines.
Palabras clave
Brighton Collaboration; CEPI; Vaccine; Benefit-risk; Safety; Protein; Recombinant; Peptide; TemplateCollections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.